Physician profile
Jeffrey Karr
NPI 1013988658
$100,805.66
in general payments reported to CMS, 2019-2025
12 companies · $4,352 in 2025
The $4,352 reported for 2025 was more than what 96% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,660 · 2020: $11K · 2021: $5,767 · 2022: $10K · 2023: $40K · 2024: $22K · 2025: $4,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $5,262 · Food and Beverage: $3,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,382.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,245.50 |
| Travel and Lodging | $5,261.67 |
| Food and Beverage | $3,165.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bone Support INC. | $39,015.06 | 2019-2025 | Ceramentbone Void Filler, Cerament G |
| Organogenesis INC. | $35,437.75 | 2019-2025 | Puraply Antimicrobial, Nushield, Apligraf |
| Smith+Nephew, INC. | $18,830.49 | 2019-2025 | Versajet, Collagenase Santyl, Acticoat 4" X 4" |
| Osteonovus, INC. | $5,400.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $1,160.44 | 2021-2024 | Nuzyra |
| Inari Medical, INC. | $500.00 | 2021 | |
| Depuy Synthes Sales INC. | $152.00 | 2024-2025 | Motoband, Na |
| Nevro Corp. | $135.00 | 2024 | Senza |
| Pacira Pharmaceuticals Incorporated | $73.39 | 2019 | |
| Horizon Therapeutics Plc | $70.20 | 2023 | Krystexxa |
| Kci USA, INC. | $15.99 | 2023 | V.A.C. Dermatac, Activ.A.C. |
| Stryker Corporation | $15.34 | 2024 | Viaflow |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Karr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.